The Chemotherapy Foundation®

A Continuing Education Program of The Chemotherapy Foundation

www.chemotherapyfoundationsymposium.orgConference Management Director: Jaclyn Silverman

Chemotherapy Foundation SympoSium

innoVatiVe CanCer therapy For tomorroW®

Presented byThe Chemotherapy Foundation and thePage & William Black Post-Graduate School of theMount Sinai School of Medicine

NOVEMBER 8-12, 2011Tuesday-Saturday

MARRIOTT MARQUIS HOTELNEW YORK CITY, USA

Franco M. Muggia, M.D. ChairEdward P. Ambinder, M.D. Program Director & Associate ChairJanice L. Gabrilove, M.D. Associate ChairWilliam K. Oh, M.D. Associate Chair

The Greenspan Meeting XXIX

HISTORY

In Honored MemoryEzra M. Greenspan, M.D.

1919-2004Founder of the

Chemotherapy Foundation SymposiumA Pioneering Trailblazer whose Achievements are the Legacy of every Practicing Oncologist Today

A LOOK BACKWARD AND AHEADIn its fourth decade the Chemotherapy Foundation

Symposium, that began as a local cancer seminar in 1972, attracts a worldwide audience of oncologists and hematologists from the United States and Canada joined by colleagues from Nigeria, Armenia, Australia, China, the Ukraine, France, England, Croatia, Germany, Italy, Spain, Japan, Lebanon, Korea, Taiwan, Latin America, and many other countries to learn of new developments in cancer therapy.

In 1968, when oncology was a newly developing specialty for the treatment of cancer, Dr Ezra M. Greenspan, founded The Chemotherapy Foundation to raise seed money to support innovative cancer research projects. A passionate advocate for the promise of combination chemotherapy, he launched the Chemotherapy Foundation Symposium to provide a forum for clinical investigators to report on the clinical studies of new agents and regimens proving effective in managing cancer patients.

At the first Symposium in 1972, about one hundred oncologists were introduced to the emerging field of chemoimmmuno-therapy. In 1984, several hundred more oncologists were present at the first Breast Cancer Chemoprevention conference advocating clinical trials of the then newly introduced antiestrogen tamoxifen for high-risk women, a vision that was realized in the next decade with the NSABP clinical trials. Then as now, Symposium presentations have focused on practical applications for the medical oncologist.

As we enter the era of molecular targeted therapies, genomics, vaccines and other biotechnological strategies that will turn cancer from a life-threatening illness to a treatable chronic disease, we continue the mission of Ezra Greenspan whose goal was the continuing education of the oncologists who would bring the advances in oncology to better patient care and outcomes.

Innovative Cancer Therapy for Tomorrow presentations will continue to explore the significance of the new developments and the challenge of broadening the therapeutic agenda for management of cancer patients.

CONTINUING EDUCATION

PROGRAM GOALSThe extensive scope and intensive coverage of new developments in cancer therapeutics at this annual educational activity provide cancer care providers with the opportunity to learn about the new agents, new modalities, clinical trials and emerging developments that will result in continuing progress in the control and cure of cancer.

LEARNING OBJECTIVESAt the conclusion of the program, participants should be able to:1. Evaluate the potential benefits of the emerging developments in

cancer therapy.2. Employ new concepts, agents and regimens in cancer patient

management to achieve better outcomes.3. Inform patients of improved treatment options and the benefits of

enrollment in clinical trials.

TARGET AUDIENCEOncologists, Hematologists, Breast Cancer Oncologists, Gynecological Oncologists, Surgical Oncologists, Pediatric Oncologists, Radiothera-pists, Immunologists, Oncology Nurses, Nurse Practitioners, Physician Assistants, Case Managers, Pharmacists.

ACCREDITATIONPhysiciansThe Mount Sinai School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.Credit DesignationThe Mount Sinai School of Medicine designates this live activity for a maximum of 34.0 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Oncology Nurses, Nurse Practitioners, Physician Assistants, Case ManagersCME hours for the Tuesday through Friday sessions, November 8-11 may be submitted to credentialing organizations for acceptance of conversion to CE. Authorized CE contact hours for Saturday, November 12 will be determined by accrediting organizations. Applications are pending for Submission to Postgraduate Institute for Medicine (PIM), an accredited provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation, the Ameri-can Academy of Physician Assistants. Case managers may submit their ANCC credit to their respective organization.

PharmacistsPharmacists will be eligible for CEU’s for the Tuesday-Friday sessions, November 9-12 plus additional contact hours for the Saturday session on November 13 provided by the New York

State Council of Health-System Pharmacists (NYSCHP) an approved provider of continuing pharmaceutical education by the Accreditation Council for Pharmaceutical Education (ACPE). Total number of contact hours available to pharmacists will be 34.5.

Certification of Attendance will be provided to all professionals.

FACULTY DISCLOSURE POLICYIt is the policy of the Mount Sinai School of Medicine to ensure objectivity, balance, independence, transparency and scientific rigor in all CME sponsored educational activities. All faculty participating in the planning or implementation of a supported activity are expected to disclose to the audience any relevant financial relation-ships and to assist in resolving any conflict-of-interest that may arise from the situation. Presenters must also make a meaningful disclosure to the audience in their discussions of unlabeled or unapproved drugs or devices. This information will be available as part of the course material.

ADVISORY

REGISTRATION FEES$525 Physicians$150 House Staff, Fellows, Oncology Nurses, Nurse Practitioners,

Physician Assistants, Case Managers, Pharmacists and other Cancer Care Providers.

$50 Tuesday Only*$50 Saturday Only*$50 Mount Sinai and Affiliated Institutions. *No fee is required for Tuesday or Saturday if you are registering for the

entire Symposium. Payment may be made by check or credit card.

$50 Oncology Practice AdministratorsFAX Registration Form. On Line Registration not Available

RefuND POliCyA 10% Administrative Charge plus the $15 processing fee will be deducted from all refunds issued. REQUESTS FOR REFUNDS RECEIVED AFTER November 3 will not be honored by the Post Graduate School of Mount Sinai.

HOTELSThe NEW YORK MARRIOTT MARQUIS located on Broadway between 45th and 46th Streets in midtown Manhattan is the Headquarters Hotel and Symposium site. Blocks of rooms at special conference rates have been set aside for symposium attendees at the Marriott and the Millennium Hotels. A block of rooms at the special conference rate of $359 per night has been reserved at the Marriott for Symposium attendees. The spacious ballroom with seating capacity for over 2,000 and large Exhibitor Pavilion make this an ideal site for all Symposium activities.

The Millennium Hotel is located on West 44th Street off Broadway about a block away from the Symposium Site. A block of rooms at the special conference rate of $329 per night has been reserved at the Millennium for Symposium attendees. Both hotels are a short bus, taxi ride or easy walk to New York City’s major attractions. Please identify yourself as a Chemotherapy Foundation Symposium attendee when making your hotel reservations. Please make your reservations early to take advantage of special Conference Rates. TO MAke ARRANgeMeNTS fOR AlTeRNATive hOTel ACCOMMODATiONS, PleASe CONTACT OuR hOuSiNg MANAgeR, DeNiSe NewMAN: Dnew229@aol.com Tel 718 835 4911, fAX 718 835 8661.

EARLY BIRD REGISTRATIONTuesday, November 8, 2 PM-9 PMPrior and New Registrants: Avoid the first-day rush on Wednesday morning. Sign-in Tuesday and pick up your Symposium Kits with the Abstracts and other meeting materials.

welCOMe BACk NeXT yeARNOveMBeR 6-10, 2012

CONFERENCE HOTEL RATE REDUCTION!Marriott Marquis $359 per night • Millennium $329 per night

Chemotherapy Foundation SympoSium

innoVatiVe CanCer therapy For tomorroW®

TUESDAY, NOVEMBER 8PEDIATRIC ONCOLOGYChair: Robert Maki, MD, PhD1:30 BONE MARROW TRANSPLANT FOR METABOLIC DISEASE Vinod K. Prasad, MD, MRCP1:45 ADVANCES IN THE TREATMENT OF ACUTE

LYMPHOBLASTIC LEUKEMIA Blythe G. Thomson, MD

2:00 FINDING CURES FOR CHILDREN AT HOME AND ABROAD: SYNERGY IN LOW, MIDDLE, AND HIGH-INCOME COUNTRIES

Scott C. Howard, MD2:15 CLINICAL TRIAL METHODS FOR RARE CANCERS J. Kyle Wathen, PhD2:30 NOVEL THERAPEUTICS I: NOTCH AND WNT SIGNALING

PATHWAYS IN PEDIATRIC MALIGNANCIES Lia Gore, MD2:45 NOVEL THERAPEUTICS II: AN APPROACH TO MELANOMA

THERAPY EMPLOYING SYNTHETIC BIOLOGY Ronald B. Herberman, MD3:00 Coffee Break3:15 THE ROLE OF SURVEILLANCE IN THE MANAGEMENT OF STAGE I

GERM CELL TUMORS Matthew D. Galsky, MD3:30 INTRA-ARTERIAL CHEMOTHERAPY FOR INTRA-OCULAR

RETINOBLASTOMA Ira J. Dunkel, MD3:45 RECENT ADVANCES IN NEUROBLASTOMA THERAPY Brian H. Kushner, MD4:00 CURRENT MANAGEMENT OF RHABDOMYOSARCOMA Alberto S. Pappo, MD4:15 OSTEOSARCOMA: CLINICAL TRIALS Richard G. Gorlick, MD4:45 OncEd and Discussion

we appreciate the indispensable role of gustave Del Toro in developing the Pediatric Oncology Program of the Chemotherapy foundation Symposium.

Conference highlightswednesday keynote Speaker James f. holland, MDThursday ezra M. greenspan Memorial lecture Martine Piccart, MDfriday Judah folkman Memorial lecture Norman wolmark, MD

WEDNESDAY, NOVEMBER 97:00 Breakfast with the Professors STATUS OF PCI 32765 IN CLL AND ITS POTENTIAL

ROLE IN LYMPHOMA John Byrd, MD IMIDS IN MULTIPLE MYELOMA Kenneth Anderson, MD

8:00 welCOMe Edward Ambinder, MD, Steven Burakoff, MD, Janice Gabrilove, MD

MORNING SESSIONHEMATOLOGIC MALIGNANCIESModerators: Janet Cuttner, MD, Janice L. Gabrilove, MD, Kanti Rai, MDMyeloproliferative Disease (MPD)8:10 JAK INHIBITORS: UPDATE AND EVALUATION Richard Silver, MD8:25 DRUG COMBINATIONS FOR MYELOPROLIFERATIVE

NEOPLASMS Ronald Hoffman, MDMyelodysplastic Syndrome (MDS) 8:40 UNIFYING THEMES IN EVOLVING CLINICAL AND

BIOLOGIC INSIGHTS Azra Raza, MDALL8:55 MONOCLONAL ANTIBODIES: TARGETED THERAPIES Hagop Kantarjian, MDAML9:10 MOLECULAR PROFILING IN AML: CLINICAL IMPLICATIONS Janice Gabrilove, MD9:25 MOVING BEYOND “7 AND 3”- NEW TREATMENT STANDARDS Gail Roboz, MD9:40 STUDIES OF CPX-351 Jeffrey Lancet, MDCLL9:55 OVERVIEW OF NEW DRUGS Kanti Rai, MD10:10 Coffee BreakCML10:40 SECOND GENERATION TYROSINE INHIBITORS VS IMATINIB: FRONT LINE Jorge Cortes, MDLymphomas10:55 NOVEL AGENTS IN HODGKIN’S LYMPHOMA Anas Younes, MD11:10 NEW APPROACHES IN MANTLE CELL LYMPHOMA John Leonard, MDMultiple Myeloma11:25 CARLFILZOMIB AND OTHER NEW PROTEOSOME INHIBITORS James Berenson, MD11:40 OncEd and Discussion

12:00 Lunch & Presentations STATE OF THE ART IN GIST: ADJUVANT THERAPY AND MUTATIONAL ANALYSIS Charles Blanke, MD IS THERE ROOM FOR OTHER ANGIOGENESIS INHIBITORS? Jordan Berlin, MD

AFTERNOON SESSION1:15 KEYNOTE SPEAKER THE ONCOLOGIC TIME WARP James Holland, MD GI CANCERSModerators: Jordan Berlin, MD, Steven Itzkowitz, MD, Howard Hochster, MD1:50 ANTIBODY-DRUG-CONJUGATES (ADC)

Olivier Rixe, MDColorectal Cancer2:05 FOLFIRI+CETUXIMAB IN ADJUVANT THERAPY Emily Chan, MD 2:20 VEGF-TRAP: A NEW PLAYER IN ANGIOGENESIS Paolo Hoff, MD 2:35 ACTIVE NEW AGENTS John Marshall, MD2:50 Coffee Break3:20 THE P13K PATHWAY Leonard Saltz, MD3:35 VITAMIN D: REDUCING CANCER RISK? Marwan Fakih, MDPancreatic Cancer3:50 MOVING FORWARD IN THE ERA OF FOLFIRINOX Eileen Mary O’Reilly, MDGastric Cancer4:05 THE HEDGEHOG INHIBITOR Deirdre Cohen, MD4:20 TELATINIB IN ADVANCED GASTRIC CANCER Jaffer Ajani, MD GIST - ADJUVANT THERAPY AND MUTATIONAL ANALYSIS Charles Blanke, MDHepatocellular Cancer4:35 NOVEL ANTIBODY TO ALK1 AFFECTING TGF BETA

AND ANGIOGENESIS Hossein Borghaei, MD

7-9 PM Dinner and Presentation

Wednesday, NOVEMBER 9 continued

THURSDAY, NOVEMBER 10

7:00 Breakfast with the Professors PROSPECTIVE ON THE LAST TWENTY FIVE YEARS:

EMERGING EVIDENCE AND GENETIC STRATEGIES Franco Muggia, MD IMMUNOTHERAPY OF OVARIAN CANCER George Coukos, MD

MORNING SESSIONModerators: Franco M. Muggia, MD, Carmel Cohen, MD, Tamar Safra, MDGYNECOLOGICAL CANCERSOvarian Cancer8:00 INTRAPERITONEAL THERAPY: CURRENT QUESTIONS Franco Muggia, MD8:15 IMPACT OF BEVACIZUMAB ON FRONT LINE AND

RECURRENCE IN OVARIAN CANCER Michael Bookman, MD8:30 ACTIVE NEW AGENTS IN OVARIAN CANCER Bradley Monk, MD8:45 PHASE 2 TRIAL OF EPITHELIAL OVARIAN CANCER

TREATED WITH XL184 Ronald Buckanovich, MD9:00 RESULTS OF TWO PARP TRIALS Bhavana Pothuri, MD9:15 ROLE OF DOXIL AND CARBOPLATIN IN

SECOND LINE TREATMENT Tamar Safra, MD9:30 OVERVIEW: STATUS OF ENDOMETRIAL CANCER Vicky Makker, MD9:45 ISSUES IN TREATMENT OF RECURRENT OVARIAN CANCER IN

THE ERA OF BEVACIZUMAB William McGuire, MD10:00 Coffee Time10:30 OncEd and DiscussionHEAD AND NECK CANCERSModerator: Missak Haigentz Jr., MDOropharynx10:55 HPV RELATED CANCER Marshall Posner, MDThyroid11:10 NEW AGENTS IN THYROID CANCER THERAPY Jochen Lorch, MD11:25 CLINICAL HETEROGENEITY IN PAPILLARY

THYROID CARCINOMA Kepal Patel, MD11:40 OncEd and Discussion

12 Noon Lunch & Presentations OBESITY, AROMATASE INHIBITORS:

THE CONNECTING LINKS Andrew Dannenberg, MD TOPIC TO BE ANNOUNCED Speaker to be Announced

THURSDAY, NOVEMBER 10

1:20 EZRA M. GREENSPAN MEMORIAL LECTURE CURE OF HER2 POSITIVE BREAST CANCER WITH NO OR MINIMAL CHEMOTHERAPY AT THE DOOR STEP? Martine Piccart, MD

AFTERNOON SESSIONBREAST CANCERModerators: Harold Burstein, MD, Seymour Cohen, MD, George Raptis, MD1:40 CIRCULATING TUMOR CELLS Daniel Hayes, MD1:55 UPDATE ON DATA REPORTS ON ANTI-HER2 THERAPY:

LAPATINIB+TRASTUZUMAB Harold Burstein, MD2:10 UPDATE ON PREVENTIVE EFFICACY OF AROMATASE INHIBITORS Paul Goss, MD2:25 PARP INHIBITION IN TRIPLE NEGATIVE BREAST CANCER Daniel Silver, MD2:40 NSABP DATA: BEVACIZUMAB FOR TRIPLE-NEGATIVE BREAST CANCER Adam Brufsky, MD2:55 Coffee Time3:25 SENTINAL LYMPH NODE BIOPSY: A SURGEON’S PERSPECTIVE Hiram Cody, MD3:40 SENTINAL LYMPH NODE BIOPSY:

AN ONCOLOGIST’S PERSPECTIVE Clifford Hudis, MD 3:55 TAMOXIFEN AND CYP2D6: LOST IN TRANSLATION? George Raptis, MD4:10 EVALUATING SINGLE-AGENT NKTR-102 IN METASTATIC BREAST CANCER Edith Perez, MD 4:25 OncEd and Discussion

7-9 PM Dinner & Presentation

FRIDAY, NOVEMBER 11

7:00 Breakfast with the Professors Chair: William Oh, MD A VALIDATED WHOLE BLOOD RNA SIGNATURE FOR

SURVIVAL IN CRPC William Oh, Md MOLECULAR DIAGNOSTICS IN GU CANCERS:

CTCS AND BEYOND CTCS: Overview and Applications in Bladder Cancer Matt Galsky, MD Prostate Cancer and CTCs: Are We Hitting the Target? Daniel Danila, MD

MORNING SESSIONURO-ONCOLOGY Moderators: Anna Ferrari, MD, William Oh, MDProstate Cancer8:00 NEW AND NOVEL AGENTS Oliver Sartor, MD8 15 POMEGRANATE EXTRACT FOR RISING PSA Michael Carducci, MD8:30 XL184 IN METASTATIC CASTRATION RESISTANT

PROSTATE CANCER David Smith, MD8:45 OPTIMIZING PATIENT SELECTION FOR SIPULEUCEL-T

IN PROSTATE CANCER Simon Hall, MD9:00 INTERMITTENT ANDROGEN SUPPRESSION FOR PROSTATE CANCER Laurence Klotz, MD9:15 LENOLIDOMIDE/DOCETAXEL IN CRPC Daniel Petrylak, MDRenal Cancer9:30 AXINITIB IN RCC Brian Rini, MD9:45 PD-1 ANTIBODY IN RCC David McDermott, MD10:00 Coffee TimeBladder Cancer10:15 NEW THERAPIES IN BLADDER CANCER Noah Hahn, MD10:30 OncEd and Discussion

LUNG CANCERModerators: Chandra P. Belani, MD, Roman Perez-Soler, MDNSCLC10:45 PERSONALIZED THERAPY AND RECENT CHANGES IN TREAT-

MENT PARADIGM Chandra P. Belani, MD11:10 ANTI-ANGIOGENIC AGENTS Roman Perez-Soler, MDSCLC11:25 NOVEL AGENTS AND FUTURE DIRECTIONS : Corey Langer, MD11:40 OncEd and Discussion

12:00 Lunch & Presentations Novel Agents in Lung Cancer HDAC Inhibitors: Suresh Ramalingam Talactoferrin: Jeffrey Crawford MetMAb and ARQ 197: Paul Bunn, MD Farletuzumab: Chandra P.Belani, MD

AFTERNOON SESSION1:00 JUDAH FOLKMAN MEMORIAL LECTURE ANTI-ANGIOGENESIS: PARADISE LOST? Norman Wolmark, MD

DIVERSE TOPICSModerators: Edward Ambinder, MD, Sylvia Adams, MD

1:20 SARCOMA MOLECULAR SIGNATURES: CLASSIFICATION, RESPONSE, OUTCOMES Paul Meltzer, MD1:35 MELANOMA: NOVEL NEW AGENTS Jeffrey Sosman, MD1:50 BONE-TARGETED AGENTS: INTEGRATED EFFICACY ANALYSIS IN SOLID TUMORS Allan Lipton, MD2:05 THE ELDERLY CANCER PATIENT: ASSESSMENT AND MANAGE-

MENT IN A SPECIAL-NEEDS POPULATION Stuart Lichtman, MD2:20 PREDICTIVE AND PROGNOSTIC TOOLS FOR EHR WEB APPS Kevin Hughes, MD2:35 NEW PRACTICE MODELS FOR ONCOLOGY Peter Bach, MD2:55 SAVING LIVE CME: WHAT CAN YOU DO? Edward Ambinder, MD3:15 WRAP UP

FRIDAY, NOVEMBER 11 continued

New Perspectives in Oncology PracticeSaturday, November 12, 8 AM - 4:25 PM

Empowering the Clinical Care TeamOncology Nurses, Nurse Practitioners, Physician Assistants,

Case Managers, Pediatric Oncology Nurses, Pharmacists

Oncologic EmergenciesAML in Older AdultsHealth Care ReformIron OverloadCancer Pain ManagementCancer Care for ElderlyBone Health in Cancer SurvivorsNew Drug UpdateTriple Negative Breast Cancer

Adolescents and Young Adults with Sarcoma

Compassion FatigueRadiation Therapy Skin ReactionsPostoperative Complications in

Ovarian CancerWomen’s Risk AssessmentProviders and Patients in

Cyberspace

A Program Overview

The collaboration of the Tisch Cancer Institute and the NYU Oncology Division in developing the Agenda for the 2011 Symposium is appreciated.

SPECIAL EVENTS

NOV 10T

HU

R NOV 11F

RI

Breakfast with the ProfessorsSTATUS OF PCI 32765 IN CLL AND ITS POTENTIAL ROLE IN LYMPHOMAJohn Byrd, MDIMIDS IN MULTIPLE MYELOMAKenneth Anderson, MDLUNCH AND PRESENTATIONSSTATE OF THE ART IN GIST: ADJUVANT THERAPY AND MUTATIONAL ANALYSISCharles Blanke, MDIS THERE ROOM FOR OTHER ANGIOGENESIS INHIBITORS? Jordan Berlin, MDKEYNOTERTHE ONCOLOGIC TIME WARPJames Holland, MD

Breakfast with the ProfessorsPROSPECTIVE ON THE LAST TWENTY FIVE YEARS:EMERGING EVIDENCE AND GENETIC STRATEGIES Franco Muggia, MDIMMUNOTHERAPY OF OVARIAN CANCERGeorge Coukos, MDLUNCH AND PRESENTATIONSOBESITY, AROMATASE INHIBITORS: THE CONNECTING LINKS Andrew Dannenberg, MDTOPIC TO BE ANNOUNCEDSpeaker to be AnnouncedEZRA M. GREENSPAN MEMORIAL LECTURECURE OF HER2 POSITIVE BREAST CANCER WITH NO OR MINIMAL CHEMOTHERAPY AT THE DOOR STEP? Martine Piccart, MD

Breakfast with the ProfessorsChair: William Oh, MDA VALIDATED WHOLE BLOOD RNA SIGNATURE FOR SURVIVAL IN CRPCWilliam Oh, MdMOLECULAR DIAGNOSTICS IN GU CANCERS: CTCS AND BEYONDCTCS: Overview and Applications in Bladder CancerMatt Galsky, MDProstate Cancer and CTCs: Are We Hitting the Target?Daniel Danila, MDLUNCH AND PRESENTATIONSNOVEL AGENTS IN LUNG CANCERHDAC Inhibitors,Suresh RamalingamTalactoferrin, Jeffrey CrawfordMetMAb, Paul Bunn, MDFarletuzumab, Chandra Belani, MD ARQ197, To be Announced JUDAH FOLKMAN MEMORIAL LECTUREANTI-ANGIOGENESIS: PARADISE LOST? Norman Wolmark, MD

NOV 9W

ED

ANNOUNCEMENTS

CONfeReNCe highlighTSkeynote Speaker

THE ONCOLOGIC TIME WARPJames Holland, MD, Wednesday, November 9

ezra M. greenspan Memorial lectureCURE OF HER2 POSITIVE BREAST CANCER WITH NOOR MINIMAL CHEMOTHERAPY AT THE DOOR STEP?

Martine Piccart, MD, Thursday, November 10

Judah folkman Memorial lectureANTI-ANGIOGENESIS: PARADISE LOST? Norman Wolmark, MD, Friday, November 11

NewWIFI ACCESS

wednesday through fridayConference Rooms and exhibitor Areas

Free for All Symposium Attendees

PORTAMeeTiNgTake Home the Presentations

On the USB Storage Presentation Drive

Onced Mini-SessionsSelecting the Practice-Ready Therapies

Accessing Learning Resources Expanding the Symposium Educational Experience

hOSPiTAliTy SuiTe Symposium-Eve, November 8, 7-9 PM

Special NeedsAmericans with Disabilities Act: Mount Sinai School of Medicine is in full compliance with provisions of the Americans with Disabilities Act (ADA) and is accessible for individuals with special needs. If you would like to attend this conference and require any special needs or accommodations, please contact the Page and William Black Post-Graduate School of Medicine at 212-731-7950.

your Patient Care Team will be interested in New Perspectives in Oncology Practice a Continuing education program for Oncology Nurses, Nurse Practitioners, Physician Assistants, Case Managers and Pharmacists on Saturday, November 12. They may register and be accredited for the entire pro-gram including Saturday or attend on Saturday only. Programs will be sent on request.

Contact: Jaclyn.silverman@mssm.edu

REGISTRATION

SyMPOSiuM RegiSTRATiONwww.chemotherapyfoundationsymposium.org

Cut off date for on-line registration is November 3

Registration fees: Specialty Hematology Oncology Pediatric Oncology Other

*Those registering for the full Symposium pay NO ADDITIONAl fee for the Tuesday and/or Saturday Sessions. No CMe is issued for Saturday Sessions.

PLEASE Check the days/day you are attending: Wed-Fri (Full Symposium) Tues (Ped Oncology) Sat (Nursing)

RefuND POliCyA 10% administrative charge plus a $15 processing fee will be deducted from all refunds issued. ReQueSTS fOR RefuNDS ReCeiveD AfTeR NOveMBeR 4 will NOT Be hONOReD by the Post-Graduate School.

ONLINE at www.chemotherapyfoundationsymposium.org FAX this form to (212) 731-7930 Telephone Registrations are not acceptedMAIL completed form to: Page & William Black Post-Graduate School Mount Sinai School of Medicine, Box 1193 One Gustave L. Levy Pl, New York, NY 10029

*Please make checks payable to Page & William Black Post-Graduate School

Exp. Date / / Signature

Amount $Check*

Credit card #

All Breakfast, lunch and Dinner events are Complimentary

Name

Address

City State Zip Country

Tel: ( ) FAX: ( )

E-mail* * E-mail required for confirmation and credit.

MDDONURSE

NP PACM

RPhPharmD

Last Name First Name

Register:

Chemotherapy Foundation Symposiuminnovative Cancer therapy for tomorrow®

The Greenspan Meeting XXIX

November 8-12, 2011Pediatric Oncology November 8 / Nursing Oncology November 12

Our Registration Fee has remained unchanged for ten years. This year because of economic circumstances, it has been raised for physicians. It is understood that registrations already made at the previous fee level will be honored.

$525. Physicians $150. Nurse, House Staff, Fellow Pharmacist, PA’s, NP’s, Industry $50. Mount Sinai and Affiliates $50. Tuesday or Saturday Only*

For Further Information Contact: Registration/CME Office: Gina Amatruda amatrudagina@sbcglobal.net Conference Management Director: Jaclyn.silverman@mssm.edu Phone 212 866 2813 Fax 212 369 5440 www.chemotherapyfoundationsymposium.org

HOTEL RESERVATIONS

Arrival date/time: Departure date:

Name

Address

City State Zip Country

Tel: ( ) FAX:( )

E-mail Smoking Non-Smoking

Other

Credit card #

Exp. Date / / Signature

Conference RateSingle(s) or Double(s) at $329 per night for nights.

A 14.75% Sales Tax and $3.50 per night Occupancy Tax is applicable to room rate.Check in 4 PM. Check out 12 noon. A credit card or one nightdeposit is required to confirm a reservation. Late Reservations at SpecialConference Rate are subject to availability.

if you prefer other hotel arrangements, please contact our housing Manager, Denise Newman: Tel 718 835 4911, fAX 718 835 8661, e-mail Dnew229@aol.com

Make your Hotel Reservations for the Symposium at Special Conference Rates

MARRIOTT MARQUIS HOTELHeadquarters Hotel1535 Broadway, New York, NY 10036-1654 Telephone 800 266 9432

SpecialSymposium

Rate$359

SPECIAL DISCOUNT RATE $359 A 14.75% sales tax and $3.50 per night occupancy tax is applicable to room rate.

To receive discounted group rate please make your reservations prior to October 11.

NewOn Line Reservation System at Symposium Headquarters Hotel https://resweb.passkey.com/go/chemotherapy2011or call 800 266 9432

MILLENNIUM HOTELNew York Broadway145 West 44 Street at BroadwayNew York, NY 10036 TEL 212 768 4400, 800 622 5569 FAX 212 789 7630

SpecialSymposium

Rate$329

for additional information contact: dan.kavulish@mssm.edu

EXHIBITORS AND SUPPORTERS*

*Some Commitments for 2011 are Pending.

AbrAxis bioscience • AcT bioTech • Agennix

AlgeTA • Allos • Amgen • AriAd merck

AsTrAZenecA • bAyer heAlThcAre • biogen idec

bioTherAnosTics • boehringer ingelheim

brisTol-myers squibb • cAremed • cArisis

celATor PhArmAceuTicAls • celgene

cenTocor orTho bioTech • cePhAlon

chAmPions bioTechnology • dAiichi sAnkyo

demos Publishing • dendreon

diAgnocure lAbs • eisAi inc • exelixis

exPress scriPTs • genenTech biooncology

genomic heAlTh • genTA • genZyme • gileAd

glAxosmiThkline • immunomedics • lilly oncology

mcmAhon PublicATions • merck • merck oncology

micromeT • millennium medicAl Publishing

millennium: TAkedA oncology

myriAd geneTic lAborATories • nekTAr

novArTis oncology • nyu medicAl cenTer

oncomed • onyx PhArmAceuTicAls

osi oncology • PAThwork diAgnosTics

PfiZer oncology • PhArmAcyclics

PromeTheus lAborATories • ProsTrAkAn

resPonse geneTics • sAnofi-AvenTis oncology

seATTle geneTics

sigmA-TAu PhArmAceuTicAls

The chemoTherAPy foundATion

Tisch cAncer insTiTuTe • us lAbs • us oncology

vP inTernATionAl • ZioPhArm oncology

THE CHEMOTHERAPY FOUNDATION

fRee eDuCATiONAl PuBliCATiONS fROM The CheMOTheRAPy fOuNDATiON

whAT eveRy wOMAN AND heR DOCTOR ShOulD DiSCuSS ABOuT OvARiAN CANCeR - A MeDiCAl ONCOlOgiST’S PeRSPeCTive Ezra M. Greenspan, M.D, Founder of The Chemotherapy Foundation, Franco M. Muggia, M.D, Director, Medical Oncology, New York University School of Medicine, Chairman and Medical Director, The Chemotherapy Foundation.

whAT eveRy MAN ShOulD kNOw ABOuT PROSTATe CANCeRAnna Ferrari, M.D., Co-Director, GU Cancer Program, New York University Medical Center

CheMOTheRAPy TODAy – A guide for Cancer Patients and Those who Care About ThemMary-Ellen Siegel, M.S.W., A.C.S.W., Clinical Instructor, Department of Community and Preventive Medicine, Mount Sinai School of Medicine, Social Work Consultant, The Chemotherapy Foundation, in collaboration with Franco M. Muggia, M.D. Professor of Medicine/Medical Oncology, New York University School of Medicine, Chairman and Medical Director, The Chemotherapy Foundation

Order from:The Chemotherapy foundation183 Madison Avenue, New York, NY 10016Contact: scox@chemotherapyfoundation.org

Partners for ProgressNew york Oncology educational Alliance

Columbia university Medical Centerlong island Jewish Medical CenterMontefiore-einstein Cancer Center

Mount Sinai Medical Center Nyu Medical Center

SuNy Downstate Medical Centerweill Medical College of Cornell university

FACULTY

Sylvia Adams, MD Assistant Professor, NYU Cancer Center, New York, NYJaffer A. Ajani, MD Professor, GI Medical Oncology, University of Texas, M.D. Anderson Cancer Center, Houston, TXEdward P. Ambinder, MD Associate Chairman and Program Director, Chemotherapy Foundation Symposium and Clinical Professor of Medicine, Mount Sinai School of Medicine, New York, NYKenneth Anderson, MD Kraft Family Professor of Medicine, Chief Division of Hematologic Neoplasia, Director Lipper Myeloma Center and Lebow Institute for Myeloma Therapeutics, Harvard Medical School, Dana Farber Cancer Institute, Boston, MAPeter Bach, MD, MAPP Assistant Professor of Clinical Public Health, Attending Physician, Memorial Sloan-Kettering Cancer Center, New York, NYChandra P. Belani, MD Miriam Beckner Professor of Medicine, Penn State Cancer Institute, Deputy Director, Penn State Cancer Institute, Hershey, PAJames R. Berenson, MD Chief Executive Officer & President, Medical & Scientific Director, Institute for Myeloma and Bone Cancer Research, West Hollywood, CAJordan D. Berlin, MD Clinical Director, GI Oncology Program, Vanderbilt-Ingram Cancer Center, Associate Professor of Medicine, Vanderbilt-Ingram Cancer Center, Nashville, TNCharles D. Blanke, MD, FACP, FRCPC Head, Division of Medical Oncology, University of British Columbia, Vancouver, British Columbia, CanadaMichael A. Bookman, MD Professor of Medicine, Chief, Hematology-Oncology, Arizona Cancer Center, Tucson, AZ Hossein Borghaei, DO, MS Director, Thoracic Medical Oncology, Co-Leader, Thoracic Cancer Service Line, Fox Chase Cancer Center, Philadelphia, PAAdam M. Brufsky, MD, PhD Professor of Medicine, Department of Medicine, Division of Hematology-Oncology, University of Pittsburgh School of Medicine, Co-Director of the Magee-Womens Breast Cancer Program of UPMC Cancer Centers, Co-Leader for Breast Cancer, University of Pittsburgh Cancer Institute, Pittsburgh, PARonald J. Buckanovich, MD, PhD Assistant Professor of Internal Medicine and Obstetrics and Gynecology, University of Michigan Comprehensive Cancer Center, Ann Arbor, MIPaul A. Bunn, Jr, MD Professor, James Dudley Chair in Cancer Research, School of Medicine, University of Colorado, Denver, COSteven J. Burakoff, MD Professor of Medicine, Professor of Oncological Sciences, Director of Mount Sinai Cancer Institute, New York, NYHoward A. Burris III, MD Chief Medical Officer, Director of Drug Development, The Sarah Cannon Cancer Center, Nashville, TNHarold J. Burstein, MD, PhD Assistant Professor of Medicine, Department of Medical Oncology, Solid Tumor Oncology, Assistant Professor, Department of Breast Oncology, Dana-Farber Cancer Institute, Boston, MAJohn C. Byrd, MD Director, Division of Hematology, The Ohio State University, Columbus, OHMichael A. Carducci, MD AEGON Professor in Prostate Cancer Research, Professor of Oncology and Urology, Prostate Cancer Program/Chemical Therapeutics Program, Johns Hopkins Kimmel Cancer Center, Baltimore, MDEmily Chan, MD, PhD Assistant Professor of Medicine, Vanderbilt University Medical Center, Nashville, TNHiram S. Cody, MD, FACS Professor of Clinical Surgery, Attending Surgeon, Breast Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NYCarmel Cohen, MD Professor of Obstetrics and Gynecology, Department of Obstetrics and Gynecology, The Mount Sinai Medical Center, New York, NYDeirdre J. Cohen, MD Assistant Professor of Medicine, Division of GI Oncology, NYU Cancer Center, New York, NY Seymour Cohen, MD Associate Clinical Professor of Medicine, Mount Sinai School of Medicine, New York, NYJorge E. Cortes, MD Professor of Medicine, Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX George Coukos, MD, PhD Director, Gynecologic Oncology Laboratory, Center for Research On Reproduction and Women’s Health, University of Pennsylvania Medical Center, Leader, Translational Research in Gynecologic Malignancies, The Abramson Family Cancer Research Institute, Assistant Professor, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Pennsylvania Medical Center, Philadelphia, PAJeffrey Crawford, MD Professor and Chief, Division of Medical Oncology, Duke University Medical Center, Durham, NCJanet Cuttner, MD Professor of Medical and Neoplastic Diseases, Division of Hematology Oncology, Mount Sinai School of Medicine, New York, NYDaniel C. Danila, MD Medical Oncology Fellow, Memorial Sloan-Kettering Cancer Center, New York, NYAndrew J. Dannenberg, MD Professor of Medicine, Cancer Center Director, Department of Medicine, Weill Cornell Medical College, New York, NYIra Dunkel, MD Associate Attending Physician and Associate Member, Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, NYMarwan G. Fakih, MD Associate Professor of Medicine, Department of Medicine, University at Buffalo, Associate Professor of Oncology, Section Head, GI Oncology, Department of Medicine, Roswell Park Cancer Institute, Buffalo, NYAnna C. Ferrari, MD Associate Professor of Oncology, Co-Director, Genitourinary Cancer Program, NYU Cancer Center, New York, NYJanice L. Gabrilove, MD The James F. Holland Professor of Medicine, Vice Chair, Clinical Research, The Department of Medicine, Director, Experimental Therapeutics, Division of Hematology/Oncology, Director, K30 Clinical Research Training Program (CRTP), Co-Director, Masters in Clinical Research, The Mount Sinai School of Medicine, New York, NY

FACULTY

Matthew D. Galsky, MD Assistant Professor of Medicine, Department of Medicine, Division of Hematology and Medical Oncology, Mount Sinai School of Medicine, Director, Genitourinary Medical Oncology, Tisch Cancer Institute at Mount Sinai Medical Center, New York, NYLia Gore, MD Associate Professor of Pediatrics and Medicine, University of Colorado School of Medicine, Aurora, CORichard Gorlick MD Professor and Division Chief, Pediatric Hematology-Oncology at Albert Einstein Cancer Center and The Children’s Hospital at Montefiore, Bronx, NYPaul E. Goss, MBBCH, PhD Director, Breast Cancer Research, Co-Director, Breast Cancer Disease Program, DF/HCC, Massachusetts General Hospital, Boston, MANoah M. Hahn, MD Assistant Professor, Department of Medicine, Division of Hematology/Oncology, Indiana University School of Medicine, Indianapolis, INMissak Haigentz, Jr., MD Associate Professor of Clinical Medicine, Department of Medicine (Oncology), Associate Professor of Clinical Otorhinolaryngology - Head & Neck Surgery, Department of Otorhinolaryngology - Head & Neck Surgery, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NYSimon J. Hall, MD Associate Professor & Chair, Urology, Assistant Professor, Gene and Cell Medicine, Mount Sinai Medical Center, New York, NYDaniel F. Hayes, MD Professor, Clinical Director, Breast Oncology Program, Division of Hematology Oncology, Department of Internal Medicine, University of Michigan Comprehensive Cancer Center, Ann Arbor, MIRonald B. Herberman, MD Founding Director Emeritus, University of Pittsburgh Cancer Institute, Pittsburgh, PAHoward S. Hochster, MD Associate Director, Yale Cancer Center, Professor of Medicine, Yale School of Medicine, New Haven, CTPaulo M. Hoff, MD FACP Chairman of Medical Oncology, Instituto do Cancer de Sao Paulo Otavio Frias de Oliveira, University of Sao Paulo, Executive Director, Centro de Oncologia, Hospital Sirio Libanes, Sao Paulo, BrazilRonald Hoffman, MD Professor, Medicine, Hematology and Medical Oncology, Professor Gene and Cell Medicine, Mount Sinai School Of Medicine, New York, NY James F. Holland, MD Professor, Medicine, Hematology and Medical Oncology, Professor, Oncological Sciences, Mount Sinai Medical Center, New York, NYScott C. Howard, MD, MSc Associate Professsor, University of Tennessee College of Medicine, Associate Member, St. Jude Children’s Research Hospital, Memphis, TNClifford A. Hudis, MD Chief of the Breast Cancer Medicine Service, Attending Physician, Memorial Sloan-Kettering Cancer Center, New York, NY Kevin S. Hughes, MD Associate Professor of Surgery, Harvard Medical School, Surgical Director, Breast Screening, Co-Director, Avon Comprehensive Breast Evaluation Center, Medical Director, Bermuda Cancer Genetics and Risk Assessment Clinic, Massachusetts General Hospital, Boston, MASteven H. Itzkowitz, MD Professor of Medicine, Associate Director of The Dr. Henry D. Janowitz Division of Gastroenterology, Director of the GI Fellowship Program at Mount Sinai School of Medicine, New York, NYHagop M. Kantarjian, MD Professor of Medicine, Internist, Department of Leukemia, , Chairman & Professor, Leukemia Department, MD Anderson Cancer Center, Houston, TXLaurence Klotz, MD Professor of Surgery, University of Toronto, Chairman, World Uro-Oncology Federation, Chief of Urology, Sunnybrook Health Sciences Centre, Toronto, CanadaBrian H. Kushner, MD Attending Physician and Member, Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, NYJeffrey E. Lancet, MD Associate Member, Leukemia Section Chief, Moffitt Cancer Center, Tampa, FLCorey J. Langer, MD Professor of Medicine, Hematology-Oncology Division, Abramson Cancer Center of the University of Pennsylvania, Department of Medical Oncology, Medical Director Thoracic Oncology, Director of Research, Fox Chase Cancer Center, Philadelphia, PA John P. Leonard, MD Associate Professor of Medicine, Clinical Director, Center for Lymphoma and Myeloma, Weill Medical College of Cornell University, New York Presbyterian Hospital, New York, NYStuart M. Lichtman, MD, FACP Medical Oncologist, NCCN Guidelines Taskforce for the treatment and Evaluation of Older Women with Breast Cancer, 65+ Clinical Geriatric Group, Cancer and Aging Program, Memorial Sloan-Kettering Cancer Center, New York, NYAllan Lipton, MD Professor of Medicine and Oncology, Medicine-Division of Hematology Oncology, M.S. Hershey Medical Center, Hershey, PAJochen H. Lorch, MD, MSc Clinical Instructor, Department of Medicine, Harvard Medical School, Medical Oncology, Dana-Farber Cancer Institute, Boston, MARobert G. Maki, MD, PhD Senior Faculty, Medicine, Pediatrics, Hematology/Oncology, Mount Sinai Medical Center, New York, NYVicky Makker, MD Assistant Attending Physician, Gynecologic Medical Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NYJohn L. Marshall, MD Division Chief, Associate Professor of Medicine, Chief, Division of Hematology/Oncology, Georgetown University Hospital, Associate Director, Clinical Research, Lombardi Comprehensive Cancer Center, Washington, DCDavid F. McDermott, MD Lecturer, Department of Cell Biology, Harvard Medical School, Staff Physician, Hematology/Oncology, Beth Israel Deaconess Medical Center, Boston, MAWilliam P. McGuire, MD Director, Weinberg Cancer Institute, Professor of Medicine and Oncology, Georgetown University, Baltimore, MD

FACULTY

Paul Meltzer, MD, PhD Chief of Genetics Branch, NCI Center for Cancer Research, National Institutes of Health, Bethesda, MDBradley J. Monk, MD, FACS, FACOG Professor, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Creighton University School of Medicine at St. Joseph’s Hospital and Medical Center, Phoenix, AZFranco M. Muggia, MD Professor of Oncology, New York University, Director, Division of Medical Oncology, New York University Medical Center, New York, NYLarry Norton, MD Professor, Department of Medicine, Weill Medical College of Cornell University, Deputy Physician-in-Chief for Breast Cancer Programs, Memorial Sloan-Kettering Cancer Center, New York, NYWilliam K. Oh, MD Professor of Medicine and Urology, Ezra M. Greenspan Professor of Clinical Cancer Therapeutics, Director of the Division of Hematology and Medical Oncology, Co-Director of the Prostate Cancer Program, and Associate Director for Clinical Research for The Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NYEileen M. O’Reilly, MD Associate Attending, GI Medical Oncology Service, Memorial Sloan-Kettering Cancer Center, Associate Professor of Medicine, Weill Medical College of Cornell University, New York, NYAlberto Pappo, MD Professsor, University of Tennessee College of Medicine, Associate Member, St. Jude Children’s Research Hospital, Memphis, TNKepal N. Patel, MD, FACS Assistant Professor of Surgery and Biochemistry, Division of Endocrine Surgery, NYU Langone Medical Center, New York, NYEdith A. Perez, MD Deputy Director, Mayo Clinic Cancer Center, Serene M. and Frances C. Durling Professor of Medicine, Mayo Clinic, Jacksonville, FLRoman Perez-Soler, MD Gutman Professor of Medicine, Chairman, Department of Medical Oncology, Montefiore Medical Center, Bronx, NY Daniel P. Petrylak, MD Associate Professor of Medicine, Director, Genitourinary Cancer Program, Director, Prostate Cancer Program, Herbert Irving Cancer Center, Columbia University Medical Center, New York, NYMartine Piccart-Gebhart, MD, PhD Professor of Oncology, Université Libre de Bruxelles (ULB), Director, Medicine Department, Jules Bordet Institute, Brussels, BELGIUMMarshall Posner, MD Director, Head and Neck Medical Oncology, Director, Office of Cancer Clinical Trials, Professor of Medicine, Professor of Gene and Cell Medicine, The Tisch Cancer Institute, Division of Hematology/Medical Oncology, Mount Sinai School of Medicine, New York, NYBhavana Pothuri, MD Assistant Professor, Department of Obstetrics and Gynecology (Obs/Gyn), NYU Women’s Cancer Program, NYU Langone Medical Center, New York, NYVinod K. Prasad, MD Attending Physician, Pediatric Blood and Marrow Transplant, Assistant Professor of Pediatrics, Duke University Medical Center, Pediatric Blood and Marrow Transplantation Division, Duke University, Durham, NCKanti R. Rai, MD Chief, Division of Hematology/Oncology, Long Island Jewish Medical Center, Joel Finkelstein Cancer Foundation Professor of Medicine, Albert Einstein College of Medicine, New York, NYSuresh S. Ramalingam, MD Associate Professor, Chief of Thoracic Medical Oncology, Emory University School of Medicine, Emory Winship Cancer Institute, Atlanta, GAGeorge Raptis, MD Associate Professor Medicine, Hematology and Medical Oncology, Associate Professor, Obstetrics, Gynecology and Reproductive Science, Mount Sinai School of Medicine, New York, NYAzra Raza, MD Director, MDS Center, Columbia University Medical Center, New York, NYBrian Rini, MD Associate Professor of Medicine, Cleveland Clinic, Lerner College of Medicine of Case Western Reserve University, Associate Director for Clinical Research, Cleveland Clinic Taussig Cancer Institute, Cleveland, OHOlivier Rixe, MD, PhD Professor of Medicine, Director, Experimental Therapeutics Program, Division of Hematology/Oncology, University of Cincinnati Cancer Institute, Cincinnati, OH Gail J. Roboz, MD Assistant Professor of Medicine, Director, Leukemia Program, Medicine, Hematology and Oncology, Weill Medical College of Cornell University, New York, NYTamar Safra, MD Medical Staff, Oncology Institute, Tel Aviv Sourasky Medical Center, Tel Aviv, ISRAELLeonard Saltz, MD Head, Colorectal Oncology Section, Memorial Sloan-Kettering Cancer Center, New York, NYOliver Sartor, MD Piltz Professor of Cancer Research, Departments of Medicine and Urology, Tulane University School of Medicine, New Orleans, LADaniel P. Silver, MD, PhD Assistant Professor of Medicine, Dana-Farber Cancer Institute, Boston, MARichard T. Silver, MD, FACP Attending Physician, Department of Medicine, Division of Hematology and Medical Oncology, Professor of Medicine, Weill Cornell Medical College, Cornell University, New York, NYDavid C. Smith, MD Professor of Medicine, University of Michigan, Ann Arbor, MIJeffrey A. Sosman, MD Professor of Medicine, Director, Melanoma and Tumor Immunotherapy Program, Vanderbilt-Ingram Cancer Center, Nashville, TNBlythe G. Thomson, MD Clinical Associate Professor, University of Washington School of Medicine, Pediatric Hematology Oncology Specialist, Outpatient Clinical Director, Seattle Children’s Hospital, Seattle, WAJ. Kyle Wathen, PhD Research Statistician, Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX Norman Wolmark, MD Chairman, NSABP, Chairman, Department of Human Oncology, Professor of Human Oncology, Drexel University College of Medicine, Philadelphia, PAAnas Younes, MD Professor of Medicine, Director, Clinical Investigation and Translational Research, Department of Lymphoma/Myeloma, The University of Texas M. D. Anderson Cancer Center, Houston, TX

The Chemotherapy Foundation®

SyMPOSiuM CAleNDAR2012 November 6-10 • 2013 November 5-9

MARRIOTT MARQUIS welCOMe BACk NeXT yeAR

CONTACT INFORMATIONSymposium

Jaclyn.silverman@mssm.edu 212 866 2813

New Perspectives in Oncology PracticeGina Amatruda amatrudagina@sbcglobal.net

www.chemotherapyfoundationsymposium.org

The Chemotherapy FoundationThe Chemotherapy Foundation, a non-profit organization, supports laboratory and clinical research projects at major medical institutions, symposia for the profession, and publishes informative booklets for the profession and the public. Tax-deductible contributions may be sent to 183 Madison Avenue, New York, NY 10016.

Chairman and Medical Director Franco Muggia, M.D.President Barry RichterDirector of Medical Symposia Edward Ambinder, M.D.Associate Medical Directors Edward Ambinder, M.D. Silvia Formenti, M.D. Janice Gabrilove, M.D. Howard Hochster, M.D. Steven Itzkowitz, M.D. Roman Perez-Soler, M.D.

Executive Director Shirley CoxConference Management Director Jaclyn Silverman

Clinical Advisory BoardChandra Bellani, MD Penn State Cancer InstituteJordan Berlin, MD Vanderbilt-Ingram Cancer CenterHoward Burris, MD Sarah Cannon Cancer CenterHarold Burstein, MD Dana Farber Cancer InstituteNicoletta Colombo, MD European Institute of OncologyAnna Ferrari, MD New York University School of MedicineHoward Hochster, MD Yale Cancer CenterLarry Norton, MD Memorial Sloan-Kettering Cancer CenterWilliam Oh, MD Tisch Cancer Institute, Mount Sinai School of Medicine Kanti Rai, MD Long Island Jewish Hospital, New York

The collaboration of the Tisch Cancer Institute and the NYU Oncology Division in developing the Agenda for the 2011 Symposium is appreciated.

Special ProjectsSteven Berns, MD Tisch Cancer InstituteSonia Reichen, MD Tisch Cancer Institute

The

Pag

e an

d W

illia

m B

lack

Pos

t-G

radu

ate

Sch

ool

One

Gus

tave

L. L

evy

Pla

ce -

Box

119

3N

ew Y

ork,

NY

100

29-6

574

NO

N-P

RO

FIT

OR

G.

U.S

. PO

STA

GE

PAiD

New

Bru

nsw

ick,

NJ

PE

RM

IT #

1

Ch

emo

ther

apy

fo

un

dat

ion

S

ymp

osi

um

in

nov

ativ

e C

ance

r Th

erap

y fo

r To

mo

rro

w®

Nov

embe

r 6-

12, 2

011

New

Yor

k C

ity, U

SA